Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH. [electronic resource]
Producer: 20201022Description: 190235 p. digitalISSN:- 2046-2441
- Animals
- Antigens, Neoplasm -- immunology
- Autoantigens -- immunology
- CD8-Positive T-Lymphocytes -- immunology
- Camelids, New World -- immunology
- Cancer Vaccines -- administration & dosage
- Cell Line, Tumor
- Drug Synergism
- Histocompatibility Antigens Class II -- immunology
- Interleukin-2 -- administration & dosage
- Melanoma -- drug therapy
- Mice
- Peptides -- administration & dosage
- Recombinant Proteins -- administration & dosage
- Single-Domain Antibodies -- metabolism
- Vaccines, Subunit
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
There are no comments on this title.
Log in to your account to post a comment.